New: Book online at Hello Gorgeous through Square — same-day confirmations & reminders. In-spa payments stay on Square. Questions? 630-636-6193.

Book now online
Need fast aesthetic or wellness care? Same-day consults may be available — book with our NP-led team.

#1 Best Med Spa in Oswego·We screen you like a medical practice, because we are one.(630) 636-6193

We screen you like a medical practice, because we are one.

Hello Gorgeous RX™ · Medical weight loss

A new era in weight loss science

GLP-1 receptor agonists — and dual GLP-1/GIP pathways — work with your biology, not against it. Here’s how the science behind semaglutide and tirzepatide supports appetite, metabolism, and sustainable change.

Mechanisms

How GLP-1 therapy works

01

What is GLP-1?

Glucagon-like peptide-1 (GLP-1) is an incretin hormone your gut releases after eating. It helps signal fullness, supports insulin release when blood sugar rises, and slows how quickly food leaves the stomach. GLP-1 receptor agonists are lab-engineered molecules that activate those same receptors — often with a longer half-life than natural GLP-1.

Incretin signalingPost-meal biologyReceptor agonist
02

Appetite & the brain

Research suggests GLP-1 agonists influence appetite centers in the brain — reducing “food noise” and helping many people feel satisfied with smaller portions. This is biology, not willpower failure. Individual response varies; your provider screens for safety and sets expectations at consult.

Satiety signalsCraving reductionIndividual response
03

Slower gastric emptying

GLP-1 agonists slow gastric emptying for many patients — food stays in the stomach longer, which can extend fullness after meals. That’s also why nausea can occur early in treatment and why dose titration matters.

Fullness after mealsGradual titrationSide-effect monitoring
04

Dual pathway: GLP-1 + GIP

Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors — a dual incretin approach studied in SURMOUNT trials. Semaglutide is a selective GLP-1 receptor agonist studied extensively in STEP and other trials. Which option fits you is a clinical decision after screening.

Semaglutide · GLP-1Tirzepatide · GLP-1 + GIPProvider-selected

Clinical context

The numbers — in trial context

Published trial averages — not a promise of your outcome. Your provider sets realistic expectations after screening.

~14.9%

Semaglutide (STEP 1)

Mean body-weight reduction at 68 weeks vs placebo in adults with obesity (trial context).

Up to ~20%+

Tirzepatide (SURMOUNT-1)

Mean weight reduction at highest studied doses vs placebo over ~72 weeks in obesity trials.

Millions

Real-world use

GLP-1 class medications are widely used for type 2 diabetes and chronic weight management in the U.S.

In-person

Hello Gorgeous care

NP-supervised programs in Oswego — compounded semaglutide & tirzepatide, titrated to you.

Sources

  1. 1.Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021.
  2. 2.Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.
  3. 3.Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018.
  4. 4.Aroda VR, Blonde L, Pratley RE. SNAC and oral semaglutide development. Rev Endocr Metab Disord. 2022.

Educational content only — not medical advice, prescribing, or a guarantee of results. Compounded medications are prepared by licensed pharmacies; brand names (Wegovy®, Ozempic®, Zepbound®, Mounjaro®) are registered trademarks of their respective owners. Eligibility, dosing, and monitoring require an in-person or telehealth evaluation with a licensed prescriber.

Ready when you are.

Start secure intake or book a $49 consult with our NP team in Oswego.

/glp1-weight-loss/science

Educational content only — not medical advice, prescribing, or a guarantee of results. Compounded medications are prepared by licensed pharmacies; brand names (Wegovy®, Ozempic®, Zepbound®, Mounjaro®) are registered trademarks of their respective owners. Eligibility, dosing, and monitoring require an in-person or telehealth evaluation with a licensed prescriber.